Sökning: onr:"swepub:oai:DiVA.org:umu-175373" >
Intrathecal treatme...
Intrathecal treatment trial of rituximab in progressive MS : results after a 2-year extension
-
- Bergman, Joakim (författare)
- Uppsala universitet,Umeå universitet,Neurovetenskaper,Umeå Univ, Dept Clin Sci, Umeå, Sweden,Landtblom: Neurovetenskap
-
Burman, Joachim (författare)
-
- Bergenheim, A. Tommy (författare)
- Umeå universitet,Neurovetenskaper,Umeå Univ, Dept Clin Sci, Umeå, Sweden
-
visa fler...
-
- Svenningsson, Anders (författare)
- Karolinska Institutet,Umeå universitet,Neurovetenskaper,Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Danderyd Hospital, Stockholm, Sweden,Umeå Univ, Dept Clin Sci, Umeå, Sweden; Karolinska Inst, Danderyd Hosp, Dept Clin Sci, S-18288 Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2020-09-08
- 2021
- Engelska.
-
Ingår i: Journal of Neurology. - : Springer Berlin/Heidelberg. - 0340-5354 .- 1432-1459. ; 268:2, s. 651-657
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://link.springe...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives: To evaluate the effect of intrathecally (IT) delivered rituximab as a therapeutic intervention for progressive multiple sclerosis (PMS) during a 3-year follow-up period.Methods: Participants of a 1-year open-label phase 1b study of IT delivered rituximab to patients with PMS were offered extended treatment with follow-up for an additional 2 years. During the extension phase, treatment with 25 mg rituximab was administered every 6 months via a subcutaneous Ommaya reservoir connected to the right frontal horn with a ventricular catheter.Results: Mild to moderate vertigo and nausea occurred in 4 out of 14 participants as temporary adverse events associated with IT rituximab infusion. During the entire 3-year period, two cases of low-virulent bacterial meningitis occurred, which were successfully treated. Walking speed deteriorated significantly during the study.Conclusions: IT administration of rituximab via a ventricular catheter was well tolerated. Considering the meningitis cases, the risk of infection was not negligible. The continued loss of walking speed indicates that IT rituximab was not able to stop disease progression.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- Multiple sclerosis
- Rituximab
- Intrathecal
- Progressive MS
- Treatment
- Clinical trial
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas